Kanso C, Etner J, Debré B, Zerbib M
Service d'urologie, hôpital Cochin, université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
Prog Urol. 2010 Feb;20(2):85-90. doi: 10.1016/j.purol.2009.06.007. Epub 2009 Aug 7.
Prostate cancer is the first cancer in men. Its incidence is constantly increasing. The significant evolution of diagnostic and therapeutic means during the two last decades contrasts with the scarcity of medicoeconomic studies. The aim of this review is to present a synthesis of the different studies published and to respond to questions about the economic aspects of this disease, with the evaluation of its direct and indirect costs. The cost-effectiveness and the benefits of the prevention and the screening are still being studied. The costs of the surgery and the radiotherapy are roughly similar. The new surgical techniques, especially the laparoscopic and the robotic surgeries, are not necessarily associated with higher costs, in condition of a high-volume laparoscopic surgery program and a faster discharge. The indirect costs of prostate cancer concern the loss of economic production associated with the disease and death and are more difficult to determine.
前列腺癌是男性的头号癌症。其发病率持续上升。在过去二十年中，诊断和治疗手段取得了重大进展，但医学经济学研究却较为匮乏。本综述的目的是对已发表的不同研究进行综合，并回答有关该疾病经济方面的问题，同时评估其直接和间接成本。预防和筛查的成本效益以及益处仍在研究之中。手术和放疗的成本大致相似。在高容量腹腔镜手术计划和更快出院的情况下，新的手术技术，尤其是腹腔镜手术和机器人手术，不一定会带来更高的成本。前列腺癌的间接成本涉及与疾病和死亡相关的经济生产损失，且更难确定。
